Similar articles

• Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.

  Spinella F, Rosanò L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, Bagnato A. Spinella F, et al. PLoS One. 2010 Jun 21;5(6):e11241. doi: 10.1371/journal.pone.0011241. PLoS One. 2010. Retraction in: PLoS One. 2024 Dec 5;19(12):e0315282. doi: 10.1371/journal.pone.0315282 PMID: 20574527 Free PMC article. Retracted.
• Loss of prolyl hydroxylase 1 and 2 in SM22α-expressing cells prevents Hypoxia-Induced pulmonary hypertension.

  Barnes EA, Ito R, Che X, Alvira CM, Cornfield DN. Barnes EA, et al. Am J Physiol Lung Cell Mol Physiol. 2023 Dec 1;325(6):L741-L755. doi: 10.1152/ajplung.00428.2022. Epub 2023 Oct 17. Am J Physiol Lung Cell Mol Physiol. 2023. PMID: 37847687 Free PMC article.
• Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells.

  Caprara V, Scappa S, Garrafa E, Di Castro V, Rosanò L, Bagnato A, Spinella F. Caprara V, et al. Life Sci. 2014 Nov 24;118(2):185-90. doi: 10.1016/j.lfs.2014.02.030. Epub 2014 Mar 6. Life Sci. 2014. PMID: 24607784
• Adipose Tissue Hypoxia in Obesity: Clinical Reappraisal of Hypoxia Hypothesis.

  Engin A. Engin A. Adv Exp Med Biol. 2024;1460:329-356. doi: 10.1007/978-3-031-63657-8_11. Adv Exp Med Biol. 2024. PMID: 39287857 Review.
• Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.

  Sugahara M, Tanaka T, Nangaku M. Sugahara M, et al. Kidney Int. 2017 Aug;92(2):306-312. doi: 10.1016/j.kint.2017.02.035. Epub 2017 Jun 24. Kidney Int. 2017. PMID: 28651951 Review.